← All indications
Deafness
A general term for the complete loss of the ability to hear from both ears.
Subtype terms (1)
More specific conditions that are subtypes of Deafness in the MeSH hierarchy.
Drugs by status
Phase 3 trials (1)
Phase 2 trials (3)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (15)
Organization Involved with Phase 2 Indications (31)
- Novartis
- Autifony Therapeutics Limited
- Bioelectron
- GlaxoSmithKline
- Nordmark Arzneimittel GmbH & Co. KG
- Otonomy, Inc.
- Advent Health
- McGill University
- University of Florida
- University of Michigan
- University of Toronto
- University of Colorado, Denver
- Royal National Throat, Nose and Ear Hospital
- Worldwide Clinical Trials
- Sound Pharmaceuticals
- LCR Clinical Research
- National Taiwan University
- Ludwig Maximilians University
- University of Alabama, Birmingham
- Washington University in St. Louis
- Department of Veteran Affairs
- ClinSupport GmbH
- MWI Medizinisches Wirtschaftsinstitut GmbH
- Cord Blood Registry, Inc.
- ProjectPharm s.r.o.
- X-act Cologne Clinical Research GmbH
- Hearing Health Science, Inc.
- Municipal Hospital of Tainan, Taiwan
- Government of Taiwan
- Frequency Therapeutics
- +1 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (11)